Taken together, our results suggest that while MET-CAR.CD28ζ is more potent than MET-CAR.4-1BBζ in anti-HCC activity for further development, approaches to overcome MET-CAR.CD28ζ T cell exhaustion need to be considered to improve its long-term efficacy. Here, MET is linked to hepatocellular carcinoma.